<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14185">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922218</url>
  </required_header>
  <id_info>
    <org_study_id>CNI-ENZ-2016-01</org_study_id>
    <secondary_id>IBIMA-CNIO-CP-01-2016</secondary_id>
    <nct_id>NCT02922218</nct_id>
  </id_info>
  <brief_title>PROSENZA: Prospective Multi-centre Study of Prognostic Factors in CRPC Treated With Enzalutamide</brief_title>
  <acronym>PROSENZA</acronym>
  <official_title>Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With Enzalutamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer
      Treated With Enzalutamide (PROSENZA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study to analyze prognostic factors in castration resistant prostate cancer
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prognostic value for global survival</measure>
    <time_frame>48 months</time_frame>
    <description>Independently validate the prognostic value for global survival of the expression signature in peripheral blood of nine genes characterised by Olmos et al. (Lancet Oncol., 2012) in patients with castration-resistant prostate cancer (CRPC) who are candidates for treatment with Enzalutamide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response by detecting PSA</measure>
    <time_frame>48 months</time_frame>
    <description>Analyzing the correlation between the response by detecting PSA and AR-V7 and / or presence of amplification of the androgen receptor in peripheral blood in patients with CPRC candidates for treatment with ENZALUTAMIDE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiology response</measure>
    <time_frame>48 months</time_frame>
    <description>Evaluate the correlation between radiologic detection response and AR-V7 and / or presence of amplification of the androgen receptor in peripheral blood in patients with CPRC candidates for treatment with ENZALUTAMIDE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency changes of AR-V7</measure>
    <time_frame>48 months</time_frame>
    <description>Analyzing changes in the frequency of AR-V7 and / or the presence of amplification androgen receptor in peripheral blood pre- and post-treatment in patients with CPRC candidates for treatment with ENZALUTAMIDE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic ability of AR-V7</measure>
    <time_frame>48 months</time_frame>
    <description>Studying the prognostic ability of AR-V7 detection and amplification androgen receptor in peripheral blood compared to other serum biomarkers and described tissue, such as testosterone, PTEN loss or presence TMPRSS-ERG fusion among others.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pronostic nomograms described for CRPC</measure>
    <time_frame>48 months</time_frame>
    <description>Validate in this cohort pronostic classic nomograms described previously in CPRC which consist of anatomical and pathological, clinical and analytical variables to be collected during the study</description>
  </other_outcome>
  <other_outcome>
    <measure>prognostic value for overall survival</measure>
    <time_frame>48 months</time_frame>
    <description>Validate the prognostic value for overall survival signature expression gene in whole blood from 9-genes described by Olmos et al (Lancet Oncol 2012) in a cohort of patients with CPRC candidates for treatment ENZALUTAMIDE.</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic and predictive utility of the expression signature</measure>
    <time_frame>48 months</time_frame>
    <description>To analyze the prognostic value to determine response (radiological and PSA) signature of gene expression in whole blood from 9-genes described by Olmos et al (Lancet Oncol 2012) in a cohort of patients with CPRC candidates for ENZALUTAMIDE treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explore new biomarkets</measure>
    <time_frame>48 months</time_frame>
    <description>Explore the existence of new biomarkers in whole blood that reflect somatic or germline alterations level associated with tumor dissemination, response and resistance to treatment and prognosis in patients with CPRC included in the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Analyze free circulating DNA and exosomes in selected centers for genomic and genetic studies.</measure>
    <time_frame>48 months</time_frame>
    <description>Investigate the feasibility of collecting and analyzing free circulating DNA and exosomes in selected centers for genomic and genetic studies.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant</condition>
  <condition>Enzalutamide</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <description>Enzalutamide 160 mg/day continue</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <arm_group_label>Enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paxgene and tempus tubes on baeline, pre-cycle 3 and progression Tumor paraffine sample at
      baseline
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Castration resistant Prostate Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent.

          2. Eighteen years of age or older.

          3. General health status acceptable and compatible with active treatment: ECOG ≤0-2.

          4. Histological confirmation of prostate cancer diagnosis.

          5. Prior resistance to biochemical castration with an LHRH agonist (or surgical
             castration through bilateral orchiectomy) and progression to an anti-androgen drug
             (e.g. bicalutamide, nilutamide or cyproterone acetate).

          6. Biochemical progression upon prior treatment in agreement with PSAWG2 criteria,
             confirmed by a second PSA test.

          7. Castrate levels of testosterone in peripheral blood: testosterone &lt;0.5 ng/ml.

          8. Candidates for standard treatment with enzalutamide: 160 mg continue on cycles of 28
             days.

          9. Availability of anatomopathological tumour material (e.g. a paraffin block of the
             prostatectomy or initial biopsy of the metastasis).

         10. Acceptable hematological, hepatic and renal functions and without contraindications
             for the administration of abiraterone in agreement with its respective summary of
             products characteristics.

        Exclusion Criteria:

          1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
             and who are five years cancer-free, as well as subjects with a history of skin
             cancers (of non-melanoma type) or excised in situ carcinomas.

          2. Medical histories, be they psychiatric or of any other character, which, according to
             the judgement of the investigator, might interfere with the subject's granting of
             informed consent or the safe execution of the procedures required in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Olmos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CNIO-Centro Nacionald e Investigaciones Oncológicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Olmos, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2950</phone_ext>
    <email>dolmos@cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuria Romero, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2951</phone_ext>
    <email>prostac@cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Afonso, MD</last_name>
      <phone>+34981334000</phone>
      <email>Franciso.Javier.Afonso.Afonso@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urbano Anido, MD</last_name>
      <phone>+34981950000</phone>
      <email>urbanoanido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M. Piulats, MD</last_name>
      <phone>+34932607780</phone>
      <email>jmpiulats@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, MD</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3309</phone_ext>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Viciana, MD</last_name>
      <phone>+34956032075</phone>
      <email>ruthvician@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Villatoro, MD</last_name>
      <phone>+34951976470</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Lainez, MD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>5870</phone_ext>
      <email>nuria.lainez.milagro@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Delia Garcia, MD</last_name>
      <phone>+34922678204</phone>
      <email>rdgmarrero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Medina, MD</last_name>
      <phone>+34981287499</phone>
      <phone_ext>174</phone_ext>
      <email>ana.medina@cog.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>4695</phone_ext>
      <email>rafael.morales.barrera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Crespo, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Sanchez, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa, MD</last_name>
      <phone>+34926278000</phone>
      <phone_ext>77137</phone_ext>
      <email>jvillaguzman1@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Mendez, MD</last_name>
      <phone>+34957011147</phone>
      <email>mjosemv@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Luque, MD</last_name>
      <phone>+34958020000</phone>
      <email>rluquecaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Casinello, MD</last_name>
      <phone>+34949209200</phone>
      <email>jacaes@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Arranz, MD</last_name>
      <phone>+34914269070</phone>
      <email>jarranz@oncomed.gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <phone>347328000</phone>
      <phone_ext>2951</phone_ext>
      <email>nromerol@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Berta Nasarre, PhD</last_name>
      <email>bnasarre@cnio.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leticia Rivera, CRA senior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Grau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Pacheco, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Garces, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>7332</phone_ext>
      <email>docjavip@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellanos, MD</last_name>
      <phone>+34913908339</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Castro, MD</last_name>
      <phone>+34917328000</phone>
      <phone_ext>2950</phone_ext>
      <email>ecastro@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Medina, MD</last_name>
      <phone>+34951291425</phone>
      <email>msaez.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gonzalez, MD</last_name>
      <phone>+34968360900</phone>
      <phone_ext>3807</phone_ext>
      <email>engonbil@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Olmos, MD</last_name>
      <phone>34 91 732 8000</phone>
      <phone_ext>2950</phone_ext>
      <email>dolmos@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Gala Grau, PhD</last_name>
      <phone>34697959726</phone>
      <email>gala.gala.grau.eecc@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranzazu Gonzalez, MD</last_name>
      <phone>+34871206130</phone>
      <phone_ext>76130</phone_ext>
      <email>aranzazu.gonzalezdealba@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Azpitarte, MD</last_name>
      <phone>+34 986800004</phone>
      <email>crisazpi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lorente, MD</last_name>
      <phone>+34961244000</phone>
      <email>davlorente@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 26, 2017</lastchanged_date>
  <firstreceived_date>September 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
